X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5946) 5946
Book Chapter (119) 119
Dissertation (75) 75
Publication (26) 26
Conference Proceeding (7) 7
Book / eBook (3) 3
Magazine Article (3) 3
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
nafld (4844) 4844
humans (2256) 2256
fatty liver (1880) 1880
male (1703) 1703
liver diseases (1494) 1494
gastroenterology & hepatology (1362) 1362
female (1356) 1356
liver (1351) 1351
obesity (1341) 1341
non-alcoholic fatty liver disease (1263) 1263
insulin-resistance (1122) 1122
fibrosis (1117) 1117
nash (1090) 1090
steatohepatitis (1054) 1054
metabolic syndrome (1053) 1053
middle aged (1022) 1022
steatosis (984) 984
insulin resistance (958) 958
animals (946) 946
adult (871) 871
risk factors (841) 841
hepatic steatosis (825) 825
prevalence (762) 762
nonalcoholic steatohepatitis (751) 751
fatty liver-disease (740) 740
inflammation (734) 734
nonalcoholic fatty liver disease (685) 685
liver - pathology (679) 679
mice (659) 659
liver - metabolism (594) 594
metabolism (582) 582
endocrinology & metabolism (535) 535
oxidative stress (527) 527
disease (526) 526
biochemistry & molecular biology (515) 515
analysis (513) 513
biopsy (510) 510
diagnosis (487) 487
diet (487) 487
diabetes (478) 478
aged (461) 461
risk (457) 457
non-alcoholic fatty liver disease - pathology (439) 439
body mass index (436) 436
cirrhosis (434) 434
nutrition & dietetics (420) 420
non-alcoholic fatty liver disease - metabolism (395) 395
association (387) 387
gastroenterology and hepatology (382) 382
insulin (379) 379
lipids (376) 376
fatty acids (365) 365
epidemiology (358) 358
pathogenesis (348) 348
pharmacology & pharmacy (340) 340
fatty liver - pathology (335) 335
expression (331) 331
nutritional and metabolic diseases (331) 331
mortality (327) 327
glucose (324) 324
cholesterol (319) 319
hepatology (316) 316
digestive system diseases (315) 315
liver cirrhosis (313) 313
triglycerides (302) 302
review (300) 300
population (298) 298
medicine & public health (294) 294
research (293) 293
health aspects (289) 289
type 2 diabetes (289) 289
medical research (284) 284
medicine, research & experimental (284) 284
risk-factors (284) 284
fatty liver - metabolism (282) 282
lipid metabolism (280) 280
mice, inbred c57bl (278) 278
physiological aspects (276) 276
diabetes mellitus (275) 275
non-alcoholic fatty liver disease - epidemiology (274) 274
hepatocellular-carcinoma (271) 271
non-alcoholic fatty liver disease - complications (270) 270
gene expression (268) 268
cell biology (264) 264
non-alcoholic steatohepatitis (264) 264
care and treatment (263) 263
non-alcoholic fatty liver disease - diagnosis (262) 262
disease models, animal (257) 257
biomarkers - blood (255) 255
non-alcoholic fatty liver disease - blood (250) 250
medicine, experimental (249) 249
medicine, general & internal (248) 248
natural-history (248) 248
medicine (246) 246
disease progression (245) 245
adolescent (242) 242
cross-sectional studies (241) 241
hepatocellular carcinoma (241) 241
hepatitis (240) 240
rats (239) 239
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5558) 5558
Chinese (333) 333
Japanese (95) 95
Korean (75) 75
German (61) 61
Portuguese (39) 39
French (28) 28
Spanish (28) 28
Russian (25) 25
Polish (19) 19
Czech (8) 8
Turkish (6) 6
Hungarian (5) 5
Italian (5) 5
Persian (5) 5
Norwegian (3) 3
Slovak (2) 2
Dutch (1) 1
Indonesian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Liver international, ISSN 1478-3223, 2017, Volume 37, Issue S1, pp. 97 - 103
The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in the hepatocytes, which may be an isolated event (non‐alcoholic... 
non‐alcoholic steatohepatitis (NASH) | peroxisome proliferator‐activator receptor (PPAR) agonists | farnesoid X receptor (FXR) | non‐alcoholic fatty liver disease (NAFLD) | ROS (reactive oxygen species) | glucagon‐like peptide (GLP‐1) agonist | non-alcoholic fatty liver disease (NAFLD) | glucagon-like peptide (GLP-1) agonist | peroxisome proliferator-activator receptor (PPAR) agonists | non-alcoholic steatohepatitis (NASH) | VITAMIN-E | ACID | RANDOMIZED-TRIALS | AMERICAN ASSOCIATION | FATTY LIVER-DISEASE | WEIGHT-LOSS | GLUCAGON-LIKE PEPTIDE-1 | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | GASTROENTEROLOGY & HEPATOLOGY | PENTOXIFYLLINE | Hypoglycemic Agents - therapeutic use | Liver Cirrhosis - etiology | Liver - pathology | Liver Transplantation | Humans | Risk Factors | Non-alcoholic Fatty Liver Disease - therapy | Disease Progression | Randomized Controlled Trials as Topic | Liver Neoplasms - etiology | Non-alcoholic Fatty Liver Disease - complications | Thiazolidinediones - therapeutic use | Exercise | Diet | Fibrosis | Vitamin E - therapeutic use | Carcinoma, Hepatocellular - etiology | Liver diseases | Syngeneic grafts | Pathogenesis | Liver | Pioglitazone | Viruses | Hepatocellular carcinoma | Transplantation | Infections | Steatosis | Hepatitis | Cirrhosis | Fatty liver | Cell injury | Hepatocytes | Vitamin E | Hepatitis C virus | Hepatitis C | Tocopherol | Liver transplantation | Nonalcoholic fatty liver disease (NAFLD) | Farnesoid X receptor (FXR) | Glucagon-like peptide (GLP-1) agonist | Peroxisome proliferator-activator receptor (PPAR) agonists | Nonalcoholic steatohepatitis (NASH)
Journal Article
Journal of hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1476 - 1483
Journal Article
Journal of evidence based medicine and healthcare, ISSN 2349-2562, 12/2019, Volume 6, Issue 51, pp. 3192 - 3196
BACKGROUND NAFLD has become one of the most common liver conditions throughout the world which is now increasingly diagnosed in developing countries. Most of... 
nafld | sbp | whr
Journal Article
Hepatology (Baltimore, Md.), ISSN 1527-3350, 2018, Volume 68, Issue 4, pp. 1347 - 1360
Nonalcoholic steatohepatitis (NASH) is a progressive, inflammatory form of fatty liver disease. It is the most rapidly rising risk factor for the development... 
NAFLD | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | CANCER | FATTY LIVER-DISEASE | MACROPHAGES
Journal Article
Nutrients, ISSN 2072-6643, 2013, Volume 5, Issue 5, pp. 1544 - 1560
Journal Article
Hepatology (Baltimore, Md.), ISSN 0270-9139, 2016, Volume 64, Issue 1, pp. 73 - 84
Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes... 
UNITED-STATES | MORTALITY | POPULATION | METABOLIC SYNDROME | NAFLD | RISK-FACTORS | ADULTS | FOLLOW-UP | STEATOHEPATITIS | NATURAL-HISTORY | GASTROENTEROLOGY & HEPATOLOGY | Prevalence | Comorbidity | Humans | Obesity - epidemiology | Non-alcoholic Fatty Liver Disease - epidemiology | Disease Progression | Incidence | Studies | Confidence intervals | Liver diseases | Liver | Mortality | Metabolism | Epidemiology
Journal Article
Journal Article